tetano
Editor, Senior Moderator
Cell Host Microbe
. 2020 Jul 18;S1931-3128(20)30401-7.
doi: 10.1016/j.chom.2020.07.005. Online ahead of print.
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients
Nan Wang[SUP] 1 [/SUP], Yan Zhan[SUP] 2 [/SUP], Linyu Zhu[SUP] 3 [/SUP], Zhibing Hou[SUP] 4 [/SUP], Feng Liu[SUP] 5 [/SUP], Pinhong Song[SUP] 5 [/SUP], Feng Qiu[SUP] 5 [/SUP], Xiaolin Wang[SUP] 6 [/SUP], Xiafei Zou[SUP] 6 [/SUP], Deyun Wan[SUP] 7 [/SUP], Xiaosong Qian[SUP] 7 [/SUP], Shanshan Wang[SUP] 8 [/SUP], Yabi Guo[SUP] 8 [/SUP], Hao Yu[SUP] 8 [/SUP], Miao Cui[SUP] 9 [/SUP], Gangling Tong[SUP] 10 [/SUP], Yunsheng Xu[SUP] 11 [/SUP], Zhihua Zheng[SUP] 12 [/SUP], Yingying Lu[SUP] 13 [/SUP], Peng Hong[SUP] 14 [/SUP]
Affiliations
Abstract
Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-α2b, whereas late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-α2b during the early stage of COVID-19 could induce favorable clinical responses.
Keywords: RNA virus; anti-retroviral agents; anti-viral immunity; cytokine storm syndrome; infectious disease; respiratory medicine; viral infection.
. 2020 Jul 18;S1931-3128(20)30401-7.
doi: 10.1016/j.chom.2020.07.005. Online ahead of print.
Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients
Nan Wang[SUP] 1 [/SUP], Yan Zhan[SUP] 2 [/SUP], Linyu Zhu[SUP] 3 [/SUP], Zhibing Hou[SUP] 4 [/SUP], Feng Liu[SUP] 5 [/SUP], Pinhong Song[SUP] 5 [/SUP], Feng Qiu[SUP] 5 [/SUP], Xiaolin Wang[SUP] 6 [/SUP], Xiafei Zou[SUP] 6 [/SUP], Deyun Wan[SUP] 7 [/SUP], Xiaosong Qian[SUP] 7 [/SUP], Shanshan Wang[SUP] 8 [/SUP], Yabi Guo[SUP] 8 [/SUP], Hao Yu[SUP] 8 [/SUP], Miao Cui[SUP] 9 [/SUP], Gangling Tong[SUP] 10 [/SUP], Yunsheng Xu[SUP] 11 [/SUP], Zhihua Zheng[SUP] 12 [/SUP], Yingying Lu[SUP] 13 [/SUP], Peng Hong[SUP] 14 [/SUP]
Affiliations
- PMID: 32707096
- DOI: 10.1016/j.chom.2020.07.005
Abstract
Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-α2b, whereas late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-α2b during the early stage of COVID-19 could induce favorable clinical responses.
Keywords: RNA virus; anti-retroviral agents; anti-viral immunity; cytokine storm syndrome; infectious disease; respiratory medicine; viral infection.